版本:
中国

BRIEF-Resverlogix wins Health Canada nod to test Fabry disease drug

May 30 Resverlogix Corp

* Resverlogix receives approval from health canada to proceed with fabry disease clinical trial with lead compound apabetalone

* Resverlogix- received approval from health canada, therapeutic products directorate, to proceed with clinical trial with lead compound apabetalone in patients with fabry disease Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐